ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00320788
Recruitment Status : Completed
First Posted : May 3, 2006
Results First Posted : March 1, 2012
Last Update Posted : March 1, 2012
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

April 28, 2006
May 3, 2006
December 16, 2011
March 1, 2012
March 1, 2012
April 2006
June 2008   (Final data collection date for primary outcome measure)
Mean Change of CR/LT From Baseline at Week 12 [ Time Frame: Baseline and at Week 12 ]
CR/LT measured in micrometers (µm); lower individual values represent better outcomes.
Safety, biological effect (OCT, fluorescein angiography, visual acuity)
Complete list of historical versions of study NCT00320788 on ClinicalTrials.gov Archive Site
  • Mean Percent Change of CR/LT From Baseline at Week 12 [ Time Frame: Baseline and at Week 12 ]
    CR/LT measured in micrometers (µm); a more negative percentage represents a better outcome
  • Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12 [ Time Frame: Baseline and at week 12 ]
    Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning
  • Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12 [ Time Frame: At Week 12 ]
    Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning
Pharmacokinetics, immunogenicity, quality of life
Not Provided
Not Provided
 
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration

This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD.

The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.

This is a double masked, prospective, randomized study in which five groups of approximately 30 patients meeting the eligibility criteria will be randomly assigned in a balanced ratio to receive a series of intravitreal (IVT) injections of VEGF Trap into the study eye at 4- or 12 -week intervals over a 12-week period.

After Week 12, patients will be evaluated every 4 weeks. Patients will remain on study or may be eligible to enter a long-term extension study, in which they will continue to receive VEGF Trap.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Macular Degeneration
  • Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
    Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
    Other Names:
    • VEGF Trap-Eye
    • BAY86-5321
  • Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
    Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
    Other Names:
    • VEGF Trap-Eye
    • BAY86-5321
  • Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
    Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
    Other Names:
    • VEGF Trap-Eye
    • BAY86-5321
  • Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
    Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
    Other Names:
    • VEGF Trap-Eye
    • BAY86-5321
  • Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
    Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
    Other Names:
    • VEGF Trap-Eye
    • BAY86-5321
  • Experimental: aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4
    Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
  • Experimental: aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12
    Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
  • Experimental: aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4
    Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
  • Experimental: aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12
    Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
  • Experimental: aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12
    Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
159
150
August 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subfoveal CNV secondary to AMD.
  • Central retinal (including lesion) thickness ≥ 300 µm as measured by Optical Coherence Tomography (OCT).
  • Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity of 73 letters to 34 letters.

Exclusion Criteria:

  • History of any vitreous hemorrhage within 4 weeks prior to Day 1.
  • Aphakia.
  • Significant subfoveal atrophy or scarring.
  • Prior treatment with the following in the study eye:

    • Subfoveal thermal laser therapy.
    • Submacular surgery or other surgical intervention for the treatment of AMD.
    • Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1.
    • Photodynamic therapy (PDT) within 12 weeks prior to Visit 2 (Day 1).
    • Pegaptanib sodium (Macugen) within 8 weeks of Visit 2 (Day 1).
    • Juxtascleral steroids or anecortave acetate within 24 weeks (6 months) prior to Visit 2 (Day 1).
    • Intravitreal administration of triamcinolone acetonide or other steroids within 24 weeks prior to Visit 2 (Day 1), unless no visible residue of drug substance can be seen in the vitreous cavity using indirect ophthalmoscopy.
    • Prior systemic or intravitreal treatment with VEGF Trap, ranibizumab (Lucentis) or bevacizumab (Avastin).
  • Presence of any other condition or laboratory abnormality, which, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the patient's appropriate participation in this Phase II study.
Sexes Eligible for Study: All
50 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00320788
VGFT-OD-0508
No
Not Provided
Not Provided
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Bayer
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP